RBC Capital downgraded Sarepta (SRPT) to Sector Perform from Outperform with a price target of $87, down from $161.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta price target lowered to $80 from $105 at Scotiabank
- Patient Fatality Forces Reality Check on Sarepta Therapeutics Stock (SRPT)
- Sarepta weakness ‘compelling’ buying opportunity, says Mizuho
- Sell Rating on Sarepta Therapeutics Due to Safety Concerns and Revenue Challenges for ELEVIDYS
- Sarepta Therapeutics’ Elevidys: Maintaining a Buy Rating Amid Safety Concerns and Low Adverse Effect Incidence